


AT9283 lactic acid

Cat. No.:	HY-10058
CAS No.:	896466-76-5
Molecular Formula:	C ₂₂ H ₂₉ N ₇ O ₅
Molecular Weight:	471.51
Target:	JAK; Aurora Kinase; Bcr-Abl; FLT3; Apoptosis; Autophagy
Pathway:	Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt; Cell Cycle/DNA Damage; Apoptosis; Autophagy
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	AT9283 lactic acid is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC ₅₀ s ranging from 1 to 30 nM). AT9283 lactic acid inhibits growth and survival of multiple solid tumors in vitro and in vivo ^{[1][2]} .			
IC₅₀ & Target	Aurora A	Aurora B	JAK3	JAK2
	3 nM (IC ₅₀)	3 nM (IC ₅₀)	1.1 nM	1.2 nM
	ABL(T315I) 4 nM			

CUSTOMER VALIDATION

- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
- J Adv Res. 2023 Mar 7;S2090-1232(23)00070-X.
- Cancers (Basel). 2022 Mar 19;14(6):1575.
- Patent. US20180263995A1.
- Harvard Medical School LINCS LIBRARY

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Howard S, et al. Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity. Journal of Medicinal Chemistry (2009), 52(2), 379-388.

[2]. Qi W, et al. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. Int J Cancer. 2012 Jun 15;130(12):2997-3005.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA